• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Annual Changes to the Nasdaq-100 Index®

    12/12/25 8:00:00 PM ET
    $ALNY
    $BIIB
    $CDW
    $FER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALNY alert in real time by email

    NEW YORK, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) today announced the results of the annual reconstitution of the Nasdaq-100 Index® (NDX®), which will become effective prior to market open on Monday, December 22, 2025.

    The following six companies will be added to the Index: Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), Ferrovial SE (NASDAQ:FER), Insmed Incorporated (NASDAQ:INSM), Monolithic Power Systems, Inc. (NASDAQ:MPWR), Seagate Technology Holdings plc (NASDAQ:STX), Western Digital Corp. (NASDAQ:WDC).

    The Nasdaq-100 Index is a globally recognized index that tracks the performance of 100 of the largest non-financial companies listed on the Nasdaq Stock Market® encompassing a diverse range of industries and sectors. From technology and retail to healthcare, telecommunications, biotechnology, and media, these companies collectively shape the new 21st century economy. The Nasdaq-100® is reconstituted each year in December, timed to coincide with the quadruple witch expiration Friday of the quarter.

    As of December 2025, the Nasdaq-100 Index underpins more than 200 tracking products with over $600 billion in assets under management globally, including the Invesco QQQ Trust (QQQ®), which seeks to deliver investment results that, before expenses, correspond to the performance of the Nasdaq-100 Index. In addition to QQQ, a range of derivatives and structured instruments, such as futures, options, and other products based on the Nasdaq-100 Index and the Invesco QQQ Trust trade on various exchanges.

    As a result of the reconstitution, the following six companies will be removed from the Index: Biogen Inc. (NASDAQ:BIIB), CDW Corporation (NASDAQ:CDW), GlobalFoundries Inc. (NASDAQ:GFS), Lululemon Athletica Inc. (NASDAQ:LULU), ON Semiconductor Corporation (NASDAQ:ON), The Trade Desk, Inc. (NASDAQ:TTD).

    Information

    For information about the six companies to be added to the Nasdaq-100 Index, please visit the following respective company websites:

    • Alnylam Pharmaceuticals, Inc. – https://www.alnylam.com/
    • Ferrovial SE – https://www.ferrovial.com/
    • Insmed Incorporated – https://insmed.com/
    • Monolithic Power Systems, Inc. – https://www.monolithicpower.com/
    • Seagate Technology Holdings plc – https://www.seagate.com/
    • Western Digital Corp. – https://www.westerndigital.com/



    About Nasdaq Global Indexes

    Nasdaq Global Indexes has been creating innovative, market-leading, transparent indexes since 1971. Today, our index offering spans geographies and asset classes and includes diverse families such as the Dividend and Income (includes Dividend Achievers), Dorsey Wright, Fixed Income (includes BulletShares®), Global Equity, Green Economy, Nordic, and Commodity indexes. We continuously offer new opportunities for financial product sponsors across a wide spectrum of investable products and for asset managers to measure risk and performance. Nasdaq also provides exchange listing, custom index, and design solutions to financial organizations worldwide.

    About Nasdaq

    Nasdaq (NASDAQ:NDAQ) is a leading global technology company serving corporate clients, investment managers, banks, brokers, and exchange operators as they navigate and interact with the global capital markets and the broader financial system. We aspire to deliver world-leading platforms that improve the liquidity, transparency, and integrity of the global economy. Our diverse offering of data, analytics, software, exchange capabilities, and client-centric services enables clients to optimize and execute their business vision with confidence. To learn more about the company, technology solutions, and career opportunities, visit us on LinkedIn, on X @Nasdaq, or at www.nasdaq.com

    Nasdaq®, Nasdaq-100 Index®, Nasdaq-100®, NDX®, QQQ®, and Nasdaq Stock Market® are registered trademarks of Nasdaq, Inc. The information contained above is provided for informational and educational purposes only, and nothing contained herein should be construed as investment advice, either on behalf of a particular security or an overall investment strategy. Neither Nasdaq, Inc. nor any of its affiliates makes any recommendation to buy or sell any security or any representation about the financial condition of any company. Statements regarding Nasdaq-listed companies or Nasdaq proprietary indexes are not guarantees of future performance. Actual results may differ materially from those expressed or implied. Past performance is not indicative of future results. Investors should undertake their own due diligence and carefully evaluate companies before investing. ADVICE FROM A SECURITIES PROFESSIONAL IS STRONGLY ADVISED.

    Media Relations Contact Investor Relations Contact
    Name: Maximilian Leitenberger

    Email: Maximilian.leitenberger@nasdaq.com



     Name: Index Client Services

    Email: indexservices@nasdaq.com

       

    NDAQF



    Primary Logo

    Get the next $ALNY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALNY
    $BIIB
    $CDW
    $FER

    CompanyDatePrice TargetRatingAnalyst
    Seagate Technology Holdings PLC
    $STX
    4/6/2026$468.00 → $582.00Overweight
    Morgan Stanley
    Western Digital Corporation
    $WDC
    3/31/2026$340.00Mkt Perform → Outperform
    Bernstein
    Seagate Technology Holdings PLC
    $STX
    3/30/2026$525.00Overweight
    Analyst
    Insmed Incorporated
    $INSM
    3/30/2026$212.00Equal-Weight → Overweight
    Morgan Stanley
    The Trade Desk Inc.
    $TTD
    3/18/2026$26.00Buy → Hold
    Stifel
    The Trade Desk Inc.
    $TTD
    3/18/2026$25.00Buy → Neutral
    Rosenblatt
    lululemon athletica inc.
    $LULU
    3/18/2026$215.00 → $175.00Market Perform
    Telsey Advisory Group
    Insmed Incorporated
    $INSM
    3/16/2026Buy
    Jefferies
    More analyst ratings

    $ALNY
    $BIIB
    $CDW
    $FER
    SEC Filings

    View All

    Insmed Incorporated filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - INSMED Inc (0001104506) (Filer)

    4/7/26 4:01:21 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SCHEDULE 13G filed by The Trade Desk Inc.

    SCHEDULE 13G - Trade Desk, Inc. (0001671933) (Subject)

    4/7/26 12:35:04 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    SEC Form DEFA14A filed by Alnylam Pharmaceuticals Inc.

    DEFA14A - ALNYLAM PHARMACEUTICALS, INC. (0001178670) (Filer)

    4/6/26 4:31:25 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    $BIIB
    $CDW
    $FER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Morgan Stanley reiterated coverage on Seagate Tech with a new price target

    Morgan Stanley reiterated coverage of Seagate Tech with a rating of Overweight and set a new price target of $582.00 from $468.00 previously

    4/6/26 8:58:03 AM ET
    $STX
    Electronic Components
    Technology

    Western Digital upgraded by Bernstein with a new price target

    Bernstein upgraded Western Digital from Mkt Perform to Outperform and set a new price target of $340.00

    3/31/26 8:07:13 AM ET
    $WDC
    Electronic Components
    Technology

    Analyst initiated coverage on Seagate Tech with a new price target

    Analyst initiated coverage of Seagate Tech with a rating of Overweight and set a new price target of $525.00

    3/30/26 8:20:45 AM ET
    $STX
    Electronic Components
    Technology

    $ALNY
    $BIIB
    $CDW
    $FER
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (ORIG-1) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/12/2024. Application Category: NDA, Application Number: 761347, Application Classification: Type 3 - New Dosage Form

    9/16/24 6:52:10 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for VUMERITY issued to BIOGEN INC

    Submission status for BIOGEN INC's drug VUMERITY (SUPPL-17) with active ingredient DIROXIMEL FUMARATE has changed to 'Approval' on 09/11/2024. Application Category: NDA, Application Number: 211855, Application Classification: Manufacturing (CMC)

    9/16/24 6:24:32 AM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    FDA Approval for GIVLAARI issued to ALNYLAM PHARMS INC

    Submission status for ALNYLAM PHARMS INC's drug GIVLAARI (SUPPL-7) with active ingredient GIVOSIRAN SODIUM has changed to 'Approval' on 04/29/2024. Application Category: NDA, Application Number: 212194, Application Classification: Labeling

    4/30/24 1:44:03 PM ET
    $ALNY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALNY
    $BIIB
    $CDW
    $FER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Vollero Andrew

    4 - Trade Desk, Inc. (0001671933) (Issuer)

    4/7/26 8:34:42 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    SEC Form 3 filed by new insider Vollero Andrew

    3 - Trade Desk, Inc. (0001671933) (Issuer)

    4/7/26 8:30:45 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    SEC Form 4 filed by Rajaram Gokul

    4 - Trade Desk, Inc. (0001671933) (Issuer)

    4/7/26 5:19:08 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    $ALNY
    $BIIB
    $CDW
    $FER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and CEO Green Jeffrey Terry was granted 398,089 shares and bought $148,101,266 worth of Class A Common Stock (6,000,000 units at $24.68), increasing direct ownership by 154% to 655,917 units (SEC Form 4)

    4 - Trade Desk, Inc. (0001671933) (Issuer)

    3/4/26 8:27:33 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    Director Torgeby Johan bought $958,320 worth of shares (12,000 units at $79.86), increasing direct ownership by 42% to 40,797 units (SEC Form 4)

    4 - NASDAQ, INC. (0001120193) (Issuer)

    2/19/26 4:00:18 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    Head of Pharm Ops and Tech Murphy Nicole bought $585 worth of shares (3 units at $195.03), increasing direct ownership by 0.02% to 19,611 units (SEC Form 4)

    4 - BIOGEN INC. (0000875045) (Issuer)

    2/17/26 8:16:40 PM ET
    $BIIB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALNY
    $BIIB
    $CDW
    $FER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insmed Provides Clinical Update on Phase 2b CEDAR Study

    —Study Did Not Meet Primary or Secondary Efficacy Endpoints; Insmed Will Discontinue HS Program— —Safety Was Consistent with Previous Studies and No New Safety Signals Were Identified for Either Dose of Brensocatib— BRIDGEWATER, N.J., April 7, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that the Phase 2b CEDAR study, which evaluated brensocatib in adult patients with moderate to severe hidradenitis suppurativa (HS), did not meet its primary or secondary efficacy endpoints in either the 10 mg or 40 mg tre

    4/7/26 4:01:00 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. "Clare brings more than three decades of industry experience, and we are very pleased to welcome her to the Board at this pivotal time for Stoke," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "Clare's deep regulatory strategy and drug development expertise, p

    4/7/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Nasdaq to Hold First Quarter 2026 Investor Conference Call

    NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) has scheduled its first quarter 2026 financial results announcement. Who:Nasdaq's CEO, CFO, and additional members of its senior management team  What:Review Nasdaq's first quarter 2026 financial results  When:Thursday, April 23, 2026Results Call: 8:00 AM Eastern   Senior management will be available for questions from the investment community following prepared remarks. All participants can access the conference via webcast through the Nasdaq Investor Relations website at http://ir.nasdaq.com/. Note: The press release and results presentation for the first quarter 2026 results will be posted on the Nasdaq Investor Relatio

    4/1/26 4:05:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    $ALNY
    $BIIB
    $CDW
    $FER
    Leadership Updates

    Live Leadership Updates

    View All

    Stoke Therapeutics Appoints Clare Kahn, Ph.D., to its Board of Directors

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced the appointment of Clare Kahn, Ph.D., to its Board of Directors. "Clare brings more than three decades of industry experience, and we are very pleased to welcome her to the Board at this pivotal time for Stoke," said Ian F. Smith, Chief Executive Officer and Director of Stoke Therapeutics. "Clare's deep regulatory strategy and drug development expertise, p

    4/7/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    The Trade Desk Appoints Drew Vollero to Board of Directors

    The Trade Desk (NASDAQ:TTD), the world's leading independent advertising technology company, today announced the appointment of Drew Vollero to its board of directors. Vollero brings deep financial and operational expertise, with a proven track record of helping high-growth technology companies scale and navigate complex market dynamics. With more than three decades of experience across public and private markets, he brings a strong perspective on long-term value creation and disciplined growth. Vollero currently serves as Reddit's first Chief Financial Officer (CFO), where he has built and scaled its financial infrastructure and guided the company through a successful IPO in March 2024

    3/25/26 4:05:00 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    Chip Wilson Comments on lululemon's Board Changes and Fourth Quarter and Full Year Fiscal 2025 Results

    VANCOUVER, B.C., March 18, 2026 /CNW/ -- Chip Wilson, Founder of lululemon athletica inc. (NASDAQ:LULU) ("lululemon" or the "Company") and one of lululemon's largest shareholders, today issued the following statement regarding the Company's announcement of Board refreshment and fourth quarter and full year results. "As I have communicated publicly and privately for the past several months, lululemon is in dire need of significant and substantial refreshment of the board of directors. Yesterday's announcement that David Mussafer, an overly long-tenured director with more than 14 years of total service on the Board, will not seek re-election, is another step of welcome change. His influence on

    3/18/26 8:00:00 AM ET
    $LULU
    Apparel
    Consumer Discretionary

    $ALNY
    $BIIB
    $CDW
    $FER
    Financials

    Live finance-specific insights

    View All

    Nasdaq to Hold First Quarter 2026 Investor Conference Call

    NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Nasdaq (NASDAQ:NDAQ) has scheduled its first quarter 2026 financial results announcement. Who:Nasdaq's CEO, CFO, and additional members of its senior management team  What:Review Nasdaq's first quarter 2026 financial results  When:Thursday, April 23, 2026Results Call: 8:00 AM Eastern   Senior management will be available for questions from the investment community following prepared remarks. All participants can access the conference via webcast through the Nasdaq Investor Relations website at http://ir.nasdaq.com/. Note: The press release and results presentation for the first quarter 2026 results will be posted on the Nasdaq Investor Relatio

    4/1/26 4:05:00 PM ET
    $NDAQ
    Investment Bankers/Brokers/Service
    Finance

    GlobalFoundries Announces Conference Call to Review First Quarter 2026 Financial Results

    MALTA, N.Y., March 31, 2026 (GLOBE NEWSWIRE) -- GlobalFoundries (NASDAQ:GFS) today announced that it will host a conference call on Tuesday, May 5, 2026, at 8:30 a.m. ET following the release of the company's first quarter 2026 financial results. Conference Call and Webcast Information The company will host a conference call with the financial community on Tuesday, May 5, 2026, at 8:30 a.m. ET. Interested parties may join the scheduled conference call by registering here. The company's financial results and a webcast of the conference call will be available on GlobalFoundries' Investor Relations website at https://investors.gf.com. 2026 Investor Day Following the first quarter financi

    3/31/26 7:00:00 AM ET
    $GFS
    Semiconductors
    Technology

    Biogen to Acquire Apellis, Enhancing the Company's Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology

    Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including two rare kidney diseases, and SYFOVRE® FDA-approved in geographic atrophy, an immune-mediated retinal diseaseBringing together Biogen and Apellis' commercialization capabilities will maximize the potential of both EMPAVELI® and SYFOVRE®, while Apellis' talent and expertise will accelerate Biogen's entry into nephrology and augment launch readiness for felzartamab, currently in Phase 3Acquisition is expected to bolster Biogen's near-and long-term growth prospects, adding immediate revenue from two products with significant growth potential; 2025 n

    3/31/26 6:59:00 AM ET
    $APLS
    $BIIB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    $ALNY
    $BIIB
    $CDW
    $FER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by The Trade Desk Inc.

    SC 13G/A - Trade Desk, Inc. (0001671933) (Subject)

    11/14/24 4:42:28 PM ET
    $TTD
    Computer Software: Programming Data Processing
    Technology

    Amendment: SEC Form SC 13G/A filed by Insmed Incorporated

    SC 13G/A - INSMED Inc (0001104506) (Subject)

    11/14/24 1:22:37 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Western Digital Corporation

    SC 13G/A - WESTERN DIGITAL CORP (0000106040) (Subject)

    11/14/24 1:22:34 PM ET
    $WDC
    Electronic Components
    Technology